A novel NPY Y5 receptor antagonist showed both anxiolytic and anorectic effects in rats, identifying Y5 as a dual target for anxiety and obesity — two conditions that frequently coexist.
Key findingA novel NPY Y5 receptor antagonist showed both anxiolytic and anorectic effects in rats, identifying Y5 as a dual target for anxiety and obesity — two
What the researchers found
A novel NPY Y5 receptor antagonist showed both anxiolytic and anorectic effects in rats, identifying Y5 as a dual target for anxiety and obesity — two conditions that frequently coexist.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2009.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
The novel neuropeptide Y Y5 receptor antagonist Lu AA33810 [N-[[trans-4-[(4,5-dihydro[1]benzothiepino[5,4-d]thiazol-2-yl)amino]cyclohexyl]methyl]-methanesulfonamide] exerts anxiolytic- and antidepressant-like effects in rat models of stress sensitivity.
The Journal of pharmacology and experimental therapeutics, 328(3), 900-11
Citation
Walker, Mary W; Wolinsky, Toni D; Jubian, Vrej; Chandrasena, Gamini; Zhong, Huailing; Huang, Xinyan; Miller, Silke; Hegde, Laxminarayan G; Marsteller, Douglas A; Marzabadi, Mohammad R; Papp, Mariusz; Overstreet, David H; Gerald, Christophe P G; Craig, Douglas A. (2009). The novel neuropeptide Y Y5 receptor antagonist Lu AA33810 [N-[[trans-4-[(4,5-dihydro[1]benzothiepino[5,4-d]thiazol-2-yl)amino]cyclohexyl]methyl]-methanesulfonamide] exerts anxiolytic- and antidepressant-like effects in rat models of stress sensitivity.. The Journal of pharmacology and experimental therapeutics, 328(3), 900-11. https://doi.org/10.1124/jpet.108.144634